Sirolimus Eluting Coronary Stent System
- UID
- MFG/MD/2020/000086_dd9e936185c45bb38483da5470752fd4_2ca0c6fa9c24a3258467f4af5778afb6
- Device class
- Class D
- Brand name
- TRICVALVE/ TREBLE/ TRICHOTOMIC/ TRIO/ TRICUSPIDEM
- License holder
- Relisys Medical Devices Limited
- Approving authority
- CDSCO, Zonal office, Hyderabad
- Product information
- The Relisys Sirolimus Eluting Coronary Stent System is indicated for improving luminal diameter and reducing restenosis for the treatment of de novo lesions in native coronary arteries. Sirolimus Eluting Coronary Stent System is also indicated for treatment of abrupt of threatened closure in patients with failed interventional therapy. The drug coating is intended to inhibit restenosis
Sirolimus Eluting Coronary Stent System is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/MD/2020/000086_dd9e936185c45bb38483da5470752fd4_2ca0c6fa9c24a3258467f4af5778afb6. This device is marketed under the brand name TRICVALVE/ TREBLE/ TRICHOTOMIC/ TRIO/ TRICUSPIDEM. The license holder is Relisys Medical Devices Limited, and it is classified as Device Class Class D. The approving authority is CDSCO, Zonal office, Hyderabad.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.